MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Balance Sheets Overview
Current Ratio
490.71%
Quick Ratio
490.71%
Debt to Asset Ratio
20.31%
Unit: Dollar
Assets Breakdown
Cash and cash equivalents
Right-of-use assets
Fixed assets, net
Liabilities Breakdown
Additional paid-in capital
Accumulated deficit
Deferred collaboration revenue
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
45,089,786
65,002,305
70,041,254
59,340,599
Marketable securities
-
-
0
15,956,740
Prepaid expenses and other current assets
2,289,120
1,271,514
1,742,202
2,162,696
Total current assets
47,378,906
66,273,819
71,783,456
77,460,035
Deferred offering costs
-
-
0
0
Fixed assets, net
20,544
-
-
-
Right-of-use assets
141,109
209,262
275,861
340,977
Total assets
47,540,559
66,483,081
72,059,317
77,801,012
Accounts payable
137,476
141,356
158,461
13,423
Accrued expenses
3,374,333
2,672,164
6,120,297
6,999,297
Current portion of debt
0
15,300,000
15,249,632
15,199,265
Operating lease liabilities
143,447
212,769
280,537
271,948
Deferred collaboration revenue
6,000,000
6,000,000
6,000,000
6,000,000
Total current liabilities
9,655,256
24,326,289
27,808,927
28,483,933
Operating lease liabilities, long-term
-
-
-
72,536
Long-term debt, net of current portion
-
-
0
0
Total liabilities
9,655,256
24,326,289
27,808,927
28,556,469
Common stock, voting, 0.001 par value 150,000,000 authorized and 60,321,068 and 60,162,773 shares issued and outstanding, respectively
60,321
60,321
60,163
60,163
Additional paid-in capital
530,685,127
529,506,343
528,147,480
526,679,311
Accumulated other comprehensive income
-
-
0
815
Accumulated deficit
-492,860,145
-487,409,872
-483,957,253
-477,495,746
Total stockholders equity
37,885,303
42,156,792
44,250,390
49,244,543
Total liabilities and stockholders equity
47,540,559
66,483,081
72,059,317
77,801,012
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Cash and cash
equivalents
$45,089,786
(9.33%↑ Y/Y)
Prepaid expenses and
other current assets
$2,289,120
(-13.24%↓ Y/Y)
Total current assets
$47,378,906
(-43.97%↓ Y/Y)
Right-of-use assets
$141,109
(-65.13%↓ Y/Y)
Fixed assets, net
$20,544
Total assets
$47,540,559
(-44.05%↓ Y/Y)
Total liabilities and
stockholders equity
$47,540,559
(-44.05%↓ Y/Y)
Total stockholders
equity
$37,885,303
(-31.48%↓ Y/Y)
Total liabilities
$9,655,256
(-67.46%↓ Y/Y)
Accumulated deficit
-$492,860,145
(-4.91%↓ Y/Y)
Additional paid-in capital
$530,685,127
(1.07%↑ Y/Y)
Total current
liabilities
$9,655,256
(-67.31%↓ Y/Y)
Common stock, voting,
0.001 par value...
$60,321
(0.46%↑ Y/Y)
Deferred collaboration
revenue
$6,000,000
(0.00%↑ Y/Y)
Accrued expenses
$3,374,333
(-49.36%↓ Y/Y)
Operating lease
liabilities
$143,447
(-45.57%↓ Y/Y)
Accounts payable
$137,476
(-90.55%↓ Y/Y)
Buy us a coffee
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)